UP Govt to conduct campaign in 17 districts to eradicate filariasis
The Chief Minister has also urged everyone to consider themselves susceptible to filariasis, advocating for preventive medicine intake and securing the upcoming generation from this ailment.
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-02-02 10:39 GMT | Update On 2024-03-22 08:34 GMT
Lucknow: The Uttar Pradesh Government headed by Chief Minister Yogi Adityanath, as part of its mission to eradicate filariasis from the state, is all set to launch the Annual Mass Drug Administration (MDA) Campaign from February 5 to 15. The campaign will be conducted in 17 districts of Uttar Pradesh.
"During this campaign, proficient health workers will conduct door-to-door visits, administering filariasis prevention medication to the entire population, with the exclusion of children under two years of age, pregnant women, and those facing serious illnesses," as per a press release from the Chief Minister's Office.
It's noteworthy that the central government has set a targeted deadline of 2027 for the complete elimination of filariasis from the country.
"The Chief Minister has appealed to all residents to actively partake in the consumption of filariasis prevention medicine during the MDA rounds. Symptoms of this grave disease, caused by Culex mosquito bites, typically manifest 5 to 15 years after infection, leading to conditions like hydrocele and swelling in the extremities and breasts," the release stated.
The Chief Minister has also urged everyone to consider themselves susceptible to filariasis, advocating for preventive medicine intake and securing the upcoming generation from this ailment. Emphasising the safety of the medicine, he has encouraged its consumption even in the absence of visible symptoms, citing it as a societal imperative.
Furthermore, he has underscored the irreversible nature of the disease once contracted, with management being the only recourse. The government is resolute in its commitment, providing training and kits for the Morbidity Management and Disability Prevention (MMDP) of filariasis patients. Thus, preventive medicine intake becomes imperative in averting the onset of the disease.
"The Yogi government remains steadfast in its commitment to the mission of rendering the state filariasis-free. A key facet of this initiative involves the rigorous training of Community Health Officers (CHO) stationed at Ayushman Bharat Arogya Mandir (Health and Wellness Centres) to adeptly identify filariasis patients," as per the release.
The Ekikrit Niksha Diwas (END), observed on the 15th of every month in health units, serves as a crucial platform for the identification of patients with tuberculosis, kala-azar, and filariasis.
"Meanwhile, as of June 2023, the state grapples with 51 filariasis endemic districts, identifying 90,768 lymphatic filariasis and 21,131 hydrocele patients," the release stated.
The upcoming MDA rounds, scheduled from February 10 to 28, will target districts including Amethi, Azamgarh, Ballia, Banda, Barabanki, Bareilly, Hamirpur, Jaunpur, Jalaun, Lucknow, Pilibhit, Shahjahanpur, Prayagraj, Pratapgarh, Sonbhadra, Unnao, and Varanasi for filariasis elimination.
Besides, in Amethi, Azamgarh, Ballia, Banda, Bareilly, Lucknow, Pratapgarh, Prayagraj, Unnao, and Varanasi, a triple-drug combination (Ivermectin, DEC, and Albendazole) will be administered, while in Ballia, Hamirpur, Jalaun, Jaunpur, Pilibhit, Shahjahanpur, and Sonbhadra, a double-drug combination (DEC and Albendazole) will be administered. Currently, 51 districts in the state are affected by filariasis, and MDA rounds will be conducted in other affected districts starting from August 10.
Read also: AstraZeneca Pharma India launches Centre of Excellence for severe asthma in Mumbai
Original news source: https://www.aninews.in/news/national/general-news/yogi-govt-to-launch-annual-mass-drug-administration-campaign-from-feb-5-to-15-to-eradicate-filariasis20240131204821/
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd